Skip to main content
Equibles

Christopher Martin

CEO

ADC Therapeutics SA (ADCT)

Equibles does not estimate personal net worth.

Get an email with a short summary when ADC Therapeutics SA publishes a filing, an earnings call transcript or a press release.

Get ADCT alerts

About Christopher Martin

Christopher Martin is recorded as CEO at ADC Therapeutics SA (ADCT). Christopher Martin has spoken on 4 earnings calls across 1 company, most recently for ADC Therapeutics SA on December 31, 2021. ADC Therapeutics SA is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at ADC Therapeutics SA includes Ameet Mallik (CEO and Board Member), Ron Squarer (Chairman), Jean-Pierre Bizzari (Board Member) and 6 others.

Christopher Martin on recent calls

“I'm very pleased to share our fourth quarter and full year results as we executed on our key objectives and closed out a pivotal year for ADC Therapeutics. I'm also looking forward to sharing our 2022 milestones with you.”
CEO, ADC Therapeutics SA Q4 FY2021 Earnings Call ·
“I'm very pleased to share an update of our progress during the third quarter. We successfully executed on our key objectives driving the ZYNLONTA launch, advancing the R&D pipeline and achieving several important corporate development goals.”
CEO, ADC Therapeutics SA Q3 FY2021 Earnings Call ·
“And thank you, everyone, for joining us today. The second quarter was nothing less than transformative for our company, as we received our first accelerated FDA approval and brought ZYNLONTA with its broad label and differentiated profile to this area of high unmet medical need.”
CEO, ADC Therapeutics SA Q2 FY2021 Earnings Call ·
“The first few months of this year have been transformational and exciting. As you know, we were extremely pleased to receive accelerated FDA approval for Zynlonta on Friday, April 23, a month before the PDUFA date.”
CEO, ADC Therapeutics SA Q1 FY2021 Earnings Call ·

Affiliation history

Company network

Leadership on record at ADC Therapeutics SA

Recent activity